#United States #New York #Class Action #Stock Loss #Altimmune

Gross Law Firm Issues Notice to Altimmune, Inc. Shareholders

On September 8, 2025, The Gross Law Firm made a significant announcement aimed at investors of Altimmune, Inc. (NASDAQ: ALT). The firm has advised shareholders who acquired shares during the defined class period of August 10, 2023, to June 25, 2025, to consider registering for potential participation in a class action lawsuit. With the lead plaintiff deadline set for October 6, 2025, action is required soon.

Class Action Suit Overview

The allegations outlined in the class action suit stem from Altimmune's press release dated June 26, 2025, where the company disclosed topline results from the IMPACT Phase 2b MASH trial of Pemvidutide aimed at treating MASH. Despite the prior expectations set by the defendants, the results highlighted a glaring failure to achieve the statistical significance needed regarding the primary endpoint of fibrosis reduction. The company attributed this disappointing outcome partly to a higher-than-anticipated placebo response. When questioned about the implications of these results, company representatives maintained an indifferent demeanor and conveyed optimism for potential improvements in a future Phase 3 trial.

However, this troubling news triggered a dramatic investor reaction. After closing at $7.71 per share on June 25, 2025, the stock price plummeted to $3.61 the very next day—a staggering drop of 53.2% in just 24 hours.

Key Dates and Registration Process

Given the recent developments, prospective class action participants are encouraged to register their information through the Gross Law Firm's dedicated link. This registration is crucial, as it not only facilitates participation in the lawsuit but also grants investors access to monitoring software that provides ongoing updates about the case's progress.

Specifically, October 6, 2025, is the firm deadline for those wishing to aim for the position of lead plaintiff. The firm reassures that there are no fees or obligations for participating in this class action.

Why Choose The Gross Law Firm?

The Gross Law Firm is well-established in the realm of class action lawsuits, dedicating itself to protecting investors' rights against deceit, fraud, and other unethical business practices. The firm emphasizes the importance of accountability among businesses and strives to secure recovery for investors harmed by misleading statements or incomplete disclosures that led to artificial inflation of stock prices.

Altimmune investors should take this notice seriously, especially those who experienced losses during the specified class period. To learn more or to take the necessary steps towards registration, interested shareholders can follow the links provided in the announcement.

For further inquiries, shareholders are urged to contact The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Conclusion

In conclusion, Altimmune shareholders are urged to act swiftly and responsibly regarding their potential claims in this class action lawsuit. As the deadline approaches, any affected investors should ensure they register in time, as this could be a critical opportunity for recouping losses incurred during the tumultuous trading days following the disappointing trial results.